Primary OS endpoint not met vs docetaxel
Overall Survival (primary)
In the overall population, sigvotatug vedotin did not show a statistically significant improvement in overall survival (OS) compared with docetaxel in patients with previously treated locally advanced/metastatic non-squamous NSCLC (≥1 prior line). (Pfizer topline, Jun 22 2026 — discrete OS/PFS values not yet released; detailed results to follow at a future congress.)
Primary endpoint missed (overall population)Subgroup signal — one prior line (~2/3 of patients)
Pfizer reported that among patients who had received only one prior line of systemic therapy, a numerically stronger trend for OS and PFS was observed for sigvotatug vedotin versus docetaxel. The company stated this as its rationale for ongoing evaluation in earlier lines, including the Phase 3 Be6A Lung-02 study of sigvotatug vedotin plus pembrolizumab in first-line NSCLC (PD-L1 TPS ≥50%). These are sponsor-reported observations from a subgroup; no statistical conclusion was claimed.
Safety & biomarker
Safety was manageable and consistent with prior studies. In an exploratory analysis, no clear relationship between IB6 expression level and clinical response was observed, despite IB6 expression in ~90% of NSCLC tumors.
Statements from the announcement
"Although the study did not meet its overall survival endpoint, in second-line patients the data suggest a clinically meaningful survival benefit for sigvotatug vedotin over docetaxel, supporting continued scientific evaluation of sigvotatug vedotin in earlier lines in combination with immunotherapy."
— attributed to Solange Peters, MD, PhD (Lausanne University Hospital, CHUV) in the Pfizer press release"This observed clinical benefit, along with our Phase 1 combination data in the first-line setting, reinforces our confidence in the potential of the sigvotatug vedotin program, including an ongoing Phase 3 trial in combination with pembrolizumab in first-line advanced NSCLC."
— attributed to Jeff Legos, PhD, Chief Oncology Officer, Pfizer (sponsor statement)
Press & analysis
Topline SigVie-002 (prev. Be6A Lung-01): sigvotatug vedotin did not significantly improve OS vs docetaxel in the overall population; stronger OS/PFS trend in patients with one prior line (~2/3). Safety manageable; no clear IB6 expression-response.
Expectations had been high that sigvotatug vedotin could replace docetaxel; Pfizer acquired it via the $43B Seagen deal.
The first pivotal ADC readout post-Seagen missed OS vs docetaxel; Pfizer points to the 1-prior-line subgroup and the ongoing Be6A Lung-02 combo with Keytruda.
703-patient study; Solange Peters notes a clinically meaningful 2L survival signal supporting earlier-line combination evaluation.